BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21931712)

  • 1. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.
    Matulonis UA; Hirsch M; Palescandolo E; Kim E; Liu J; van Hummelen P; MacConaill L; Drapkin R; Hahn WC
    PLoS One; 2011; 6(9):e24433. PubMed ID: 21931712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.
    Kim YM; Lee SW; Chun SM; Kim DY; Kim JH; Kim KR; Kim YT; Nam JH; van Hummelen P; MacConaill LE; Hahn WC; Jang SJ
    PLoS One; 2014; 9(6):e99451. PubMed ID: 24936796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma.
    Lee J; van Hummelen P; Go C; Palescandolo E; Jang J; Park HY; Kang SY; Park JO; Kang WK; MacConaill L; Kim KM
    PLoS One; 2012; 7(6):e38892. PubMed ID: 22723903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
    Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
    BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 7. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
    Spreafico A; Oza AM; Clarke BA; Mackay HJ; Shaw P; Butler M; Dhani NC; Lheureux S; Wilson MK; Welch S; Zhang T; Yu C; Stockley T; Siu LL; Kamel-Reid S; Bedard PL
    Gynecol Oncol; 2017 Feb; 144(2):250-255. PubMed ID: 28062115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling critical cancer gene mutations in clinical tumor samples.
    MacConaill LE; Campbell CD; Kehoe SM; Bass AJ; Hatton C; Niu L; Davis M; Yao K; Hanna M; Mondal C; Luongo L; Emery CM; Baker AC; Philips J; Goff DJ; Fiorentino M; Rubin MA; Polyak K; Chan J; Wang Y; Fletcher JA; Santagata S; Corso G; Roviello F; Shivdasani R; Kieran MW; Ligon KL; Stiles CD; Hahn WC; Meyerson ML; Garraway LA
    PLoS One; 2009 Nov; 4(11):e7887. PubMed ID: 19924296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
    Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
    Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
    Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
    Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
    Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
    Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
    Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
    Auner V; Kriegshäuser G; Tong D; Horvat R; Reinthaller A; Mustea A; Zeillinger R
    BMC Cancer; 2009 Apr; 9():111. PubMed ID: 19358724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
    Encinas G; Maistro S; Pasini FS; Katayama ML; Brentani MM; Bock GH; Folgueira MA
    Rev Assoc Med Bras (1992); 2015; 61(5):474-83. PubMed ID: 26603012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    Kowalik A; Zalewski K; Kopczyński J; Siołek M; Lech M; Hińcza K; Kalisz J; Chrapek M; Zięba S; Furmańczyk J; Jedliński M; Chłopek M; Misiek M; Góźdź S
    Pol J Pathol; 2019; 70(2):115-126. PubMed ID: 31556562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.